T cell receptor therapy against melanoma-Immunotherapy for the future?

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• Malignant melanoma treatment has evolved significantly, moving from dacarbazine to targeted therapies and immune checkpoint inhibitors (ICIs).
• Despite advancements like dual ICI therapy (anti-CTLA-4 and anti-PD-1), 50% of metastatic melanoma patients remain unresponsive.
• Melanoma's high mutational burden confers increased immunogenicity, suggesting potential for novel immunotherapeutic strategies.

Purpose of the Study:

• To explore the potential of T cell receptor (TCR) therapy as an alternative or combination treatment for malignant melanoma.
• To review current applications and future implications of TCR therapy in melanoma management.
• To address the limitations of existing therapies and the need for improved treatment strategies.

Main Methods:

• Review of current literature on melanoma immunotherapy, focusing on T cell receptor (TCR) therapy.
• Analysis of melanoma's immunogenic properties due to its high mutational burden.
• Discussion of the application of TCR therapy in targeting specific antigens and private mutations.

Main Results:

• TCR therapy is a viable immunotherapy approach for melanoma, leveraging its high mutational burden.
• Current TCR therapy targets a limited antigen repertoire, but personalized approaches are expanding this scope.
• Combination strategies involving TCR therapy may improve response rates in non-responders to current treatments.

Conclusions:

• TCR therapy holds significant promise for improving outcomes in malignant melanoma, particularly for treatment-resistant cases.
• Further development and application of TCR therapy, including personalized targeting, are crucial for advancing melanoma treatment.
• Exploring TCR therapy alone or in combination is essential to overcome current treatment limitations in metastatic melanoma.